Loading...
•
Mar 31, 2025
•/
Nyxoah SA Q1 2025 Earnings Report
Nyxoah reported increased operating loss in Q1 2025 due to scale-up and commercialization efforts despite steady revenue.
Key Takeaways
Nyxoah recorded €1.1 million in revenue for Q1 2025, slightly below last year. The company's operating loss widened to €20.6 million as it ramped up expenses in preparation for the U.S. commercialization of its Genio® system. With the FDA approval process nearing completion, Nyxoah maintained a strong cash position to support its strategic objectives.
Revenue reached €1.1 million, a slight decline from Q1 2024.
Operating loss increased to €20.6 million due to commercialization and R&D expenses.
Cash and financial assets totaled €63.0 million at quarter-end.
Company anticipates FDA approval for Genio® system in Q2 2025.
Revenue by Segment
Forward Guidance
Nyxoah remains focused on receiving FDA approval in Q2 2025 and preparing for the Genio® system’s U.S. commercial launch.
Positive Outlook
- FDA Approvable Letter received for Genio® system.
- Final validation work for FDA requirements completed.
- Manufacturing site already passed prior FDA inspection.
- Strong cash position supports upcoming commercialization.
- Increased R&D spending aimed at product advancement.
Challenges Ahead
- Operating loss widened significantly compared to Q1 2024.
- Revenue declined slightly year-over-year.
- Cash and financial assets decreased from €85.6M to €63.0M.
- High SG&A expenses due to commercialization preparations.
- Continued negative net income impacts financial position.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...